Table 2

Summary of adverse events (no. (%)) in patients with osteoarthritis who received risedronate or placebo

Placebo

Risedronate

(n = 98)

5 mg/day (n = 96)

15 mg/day (n = 90)

Patients with AEs

94 (96%)

95 (99%)

84 (93%)

Dropouts due to AEs

12 (12%)

7 (7%)

10 (11%)

Overall GI AEs

15 (15%)

16 (17%)

7 (8%)

Abdominal pain

6 (6%)

7 (7%)

3 (3%)

Dyspepsia

7 (7%)

7 (7%)

3 (3%)

Gl disorder

3 (3%)

1 (1%)

1 (1%)

AE, adverse event; GI, gastrointestinal.

Spector et al. Arthritis Research & Therapy 2005 7:R625   doi:10.1186/ar1716